

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)

(Amendment No. 2)1

Pediatrics Medical Group, Inc.

(Name of Issuer)

Common Stock, \$.01 par value

(Title of Class of Securities)

705324 10 1

(CUSIP Number)

Welsh, Carson, Anderson
& Stowe
320 Park Avenue, Suite 2500
New York, New York 10022
Attention: Jonathan Rather
Tel. (212) 893-9500

Othon A. Prounis, Esq.
Reboul, MacMurray, Hewitt,
Maynard & Kristol
45 Rockefeller Plaza
New York, New York 10111
Tel. (212) 841-5700

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

August 20, 2001

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [].

1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.

1) Name of Reporting Person and I.R.S. Identification No. of Above Person, if an Entity (Voluntary) Welsh, Carson, Anderson & Stowe VII, L.P.

2) Check the Appropriate Box if a Member of a Group (a) [X] (b) []

3) SEC Use Only

4) Source of Funds Not Applicable

5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) Not Applicable

6)	Citizenship or Place of Organization		Delaware

Number of Shares Beneficially Owned by Each Reporting Person	7)	Sole Voting Power	2,757,877 shares of Common Stock
	8)	Shared Voting Power	-0-
	9)	Sole Disposi- tive Power	2,757,877 shares of Common Stock
	10)	Shared Dis- positive Power	-0-

11)	Aggregate Amount Beneficially Owned by Each Reporting Person		2,757,877 shares of Common Stock

12)	Check if the Aggregate Amount in Row (11) Excludes Certain Shares		

13)	Percent of Class Represented by Amount in Row (11)	11.7%	

14)	Type of Reporting Person		PN

1) Name of Reporting Person and I.R.S. Identification No. of Above Person, if an Entity (Voluntary) WCAS Healthcare Partners, L.P.

2) Check the Appropriate Box if a Member of a Group (a) (b)

3) SEC Use Only

4) Source of Funds Not Applicable

5) Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) Not Applicable

6) Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person	7) Sole Voting Power	57,673 shares of Common Stock
	8) Shared Voting Power	-0-
	9) Sole Dispositive Power	57,673 shares of Common Stock
	10) Shared Dispositive Power	-0-

11) Aggregate Amount Beneficially Owned by Each Reporting Person 57,673 shares of Common Stock

12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares

13) Percent of Class Represented by Amount in Row (11) 0.2%

14) Type of Reporting Person PN

Amendment No. 2 to Schedule 13D

Reference is hereby made to the statement on Schedule 13D filed with the Commission on May 22, 2001, as amended by Amendment No. 1 thereto filed on May 29, 2001 (as so amended, the "Schedule 13D"). Terms defined in the Schedule 13D are used herein as so defined.

Item 5 is hereby amended and restated to read in its entirety as follows:

Item 5. Interest in Securities of the Issuer.

The following information is based on a total of 23,640,542 shares of Common Stock outstanding as of August 7, 2001, as reported in the Issuer's Report on Form 10-Q for the period ended June 30, 2001 filed with the Commission on August 14, 2001:

(a)

WCAS VII and VII Partners

WCAS VII owns 2,757,877 shares of Common Stock, or approximately 11.7% of the Common Stock outstanding. VII Partners, as the general partner of WCAS VII, may be deemed to beneficially own the securities owned by WCAS VII.

WCAS HP and HP Partners

WCAS HP owns 57,673 shares of Common Stock, or approximately 0.2% of the Common Stock outstanding. HP Partners, as the general partner of WCAS HP, may be deemed to beneficially own the securities owned by WCAS HP.

General Partners of VII Partners and HP Partners

(i) Patrick J. Welsh owns 23,892 shares of Common Stock, or approximately 0.1% of the Common Stock outstanding.

(ii) Russell L. Carson owns 23,892 shares of Common Stock, or approximately 0.1% of the Common Stock outstanding.

(iii) Bruce K. Anderson owns 23,892 shares of Common Stock, or approximately 0.1% of the Common Stock outstanding.

(iv) Thomas E. McInerney owns 18,949 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(v) Robert A. Minicucci owns 8,238 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(vi) Anthony J. deNicola owns 2,471 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(vii) Paul B. Queally owns 4,943 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(viii) Lawrence B. Sorrel owns no shares of Common Stock.

(ix) Jonathan M. Rather owns no shares of Common Stock.

(b) The general partners of VII Partners and HP Partners may be deemed to share the power to vote or direct the voting of and to dispose or direct the disposition of the Common Stock owned by WCAS VII and WCAS HP, respectively. Each of the general partners of VII Partners and HP Partners disclaims beneficial ownership of shares of Common Stock other than those he owns directly or by virtue of his or her indirect pro rata interest, as a general partner of VII Partners and/or HP Partners, as the case may be, in the securities owned by WCAS VII and/or WCAS HP.

(c) On dates between August 14, 2001 and August 22, 2001, WCAS VII sold an aggregate 314,061 shares of Common Stock in open market transactions, at a weighted average sale price of \$36.23 per share.

(d) Except as described in this statement, no person has the power to direct the receipt of dividends on or the proceeds of sales of the shares of Common Stock owned by WCAS VII or WCAS HP.

(e) Not Applicable.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

WELSH, CARSON, ANDERSON & STOWE VII, L.P.
By: WCAS VII Partners, L.P.,
General Partner

By: /s/ Jonathan Rather

General Partner

WCAS HEALTHCARE PARTNERS, L.P.
By: WCAS HP Partners, General Partner

By: /s/ Jonathan Rather

Attorney-in-Fact

Dated: August 28, 2001